Background
==========

While much is known about metabolic syndrome and systemic vascular disease, the role of metabolic derangements on the pulmonary circulation is poorly studied \[[@b1-medscimonit-24-2655]\]. Although early closure of the cardiac shunts can obtain a favorable clinical outcome, some defects may be undetected until adulthood and are diagnosed late, when pulmonary vascular lesions have already developed \[[@b2-medscimonit-24-2655]\]. When the pulmonary vascular resistance (PVR) exceeds 5 Woods, it falls into an inoperable disease state \[[@b3-medscimonit-24-2655],[@b4-medscimonit-24-2655]\] and finally progresses to right heart failure. Therefore, slowing or even reversing the disease course is the key to improve survival.

As reported in previous studies, a variety of metabolic derangements, such as insulin resistance, hyperuricemia, and dyslipidemia, are closely related to pulmonary arterial hypertension (PAH) \[[@b5-medscimonit-24-2655]--[@b12-medscimonit-24-2655]\]. These environmental modifiers may potentiate the effect of persistent left-to-right shunting on the pulmonary vasculature, thereby triggering or worsening PAH \[[@b13-medscimonit-24-2655]\].

Therefore, we performed this study to characterize the metabolic status of patients with operable *vs.* inoperable left-to-right shunts and to determine whether these derangements are associated with a more severe disease state that hindered defect closure.

Material and Methods
====================

Study population
----------------

Adult patients diagnosed with atrial septal defect (ASD) or ventricular septal defect (VSD) were retrospectively screened at Guangdong Provincial Cardiovascular Institute from 2013 to 2015. We excluded patients with presence of extra-cardiac anomalies, co-morbidity conditions of Down Syndrome, overlapping causes of other types of pulmonary hypertension, overt diabetes, and those taking antihyperglycemic agents. Patients who were candidates for defect correction but refused to receive defect closure were also excluded. Operability of defect closure in patients with VSD/ASD and severity of pulmonary arterial hypertension were assessed by cardiac catheterization. Ethics approval was granted by the hospital Research Ethics Committee.

Definition
----------

According to the WHO definition of metabolic syndrome, we defined systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg as hypertension, plasma TRIG ≥150 mg/ml or HDLC \<40 mg/dl in men or \<50 mg/dl in women as dyslipidemia, and BMI \>30 kg/m^2^ as obesity \[[@b14-medscimonit-24-2655]\]. But for the Asian population, we defined a BMI \>25 kg/m^2^ as relatively obese. As proposed by the American Diabetes Association, an HbA1c of ≥5.7% is associated with diabetes risk and could be regarded as prediabetes \[[@b15-medscimonit-24-2655],[@b16-medscimonit-24-2655]\]. Based on the physiochemical definition of hyperuricemia, uric acid \>416 mmol/l is hyperuricemia \[[@b17-medscimonit-24-2655]\].

According to the 2010 ESC guidelines for the management of adult congenital heart disease, patients with significant shunt (Qp: Qs \>1.5 or with signs of RV volume overload) and PVR \<5 WU should undergo defect closure. Surgeries or percutaneous interventions are contraindicated for patients with PVR\>5WU and a net left-to-right shunting (Qp/Qs) less than 1.5 \[[@b3-medscimonit-24-2655]\]. Patients were divided into operable and inoperable groups based on these criteria.

Data collection
---------------

Fasting venous blood samples were drawn to measure lipid profile (total cholesterol, low-density lipoprotein, triglycerides, and high-density lipoprotein), glycosylated hemoglobin A1c (HbA1c), uric acid (UA), and NT-proBNP. From the diagnostic right heart catheterization, heart rate (HR), systemic systolic and diastolic blood pressures (shtn and dhtn), right atrial pressure (RAP), pulmonary artery pressures (PAP), pulmonary artery wedge pressure (PAWP), cardiac output (CO), and cardiac index (CI) were recorded.

Data analysis
-------------

Data was analyzed using SPSS version 20.0 software (SPSS Statistics version 20, IBM Corporation, Armonk, NY, USA). Results are expressed as mean ± standard deviation for continuous variables or as number of patients and percentages for categoric variables. Key clinical and hemodynamic parameters for operable and inoperable patients were compared using the independent-samples *t* test. Comparisons of the prevalence of prediabetes, hyperuricemia, and dyslipidemia were evaluated by the chi-square or Fisher exact test. Age, sex, uric acid, BMI, and lipid profile were used to evaluate the relationship with pulmonary vascular resistance by univariate and multivariate logistic regression model. All p-values were 2-sided, and a value at p\<0.05 was considered statistically significant.

Results
=======

Our center evaluated a total of 116 eligible patients with a mean age of 39±13 years (83 females and 33 males, ASD=76, VSD=40). Patients were divided into operable (n=73) and inoperable groups (n=43) according to 2010 ESC guidelines for the management of adult congenital heart disease \[[@b3-medscimonit-24-2655]\]. Demographics, laboratory blood test results, and hemodynamic details are shown in [Table1](#t1-medscimonit-24-2655){ref-type="table"}.

As shown in [Table 1](#t1-medscimonit-24-2655){ref-type="table"}, age, BMI, HbA1c, uric acid, and HDLC were significantly different between operable and inoperable groups (p\<0.05). Patients receiving defect correction were relative older (42±14 *vs.* 33±11, p\<0.0001) and had a lower HbA1c (5.52±0.49 *vs.* 5.71±0.41, p=0.042) and uric acid (358±105 *vs.* 406±126, p=0.029) but a higher HDLC (1.21±0.33 *vs.* 1.08±0.22, p=0.017) and BMI (20.4±3.9 *vs.* 18.8±3.1, p=0.023) ([Figure 1](#f1-medscimonit-24-2655){ref-type="fig"}).

According to the above-defined metabolic disturbances, patients in the inoperable group had a higher prevalence of prediabetes (58% *vs.* 41%, p=0.076), hyperuricemia (37.2% *vs.* 21.9, p=0.106), and dyslipidemia (74% *vs.* 56%, p=0.049), but a lower prevalence of hypertension (13.9% *vs.* 30.1%, p=0.049) and obesity (4.6% *vs.* 12.3%, p=0.301) ([Figure 2](#f2-medscimonit-24-2655){ref-type="fig"}).

On univariate logistic regression analysis, age, BMI, HbA1c, uric acid, HDLC, and blood pressure (BP) were found to be associated with pulmonary vascular resistance. However, when all these factors were entered into the multivariate logistic regression model, only age and HbA1c remained significant ([Table 2](#t2-medscimonit-24-2655){ref-type="table"}).

Discussion
==========

Metabolic syndrome is a known risk factor for coronary artery disease. However, whether a similar effect occurs in pulmonary circulation remains unclear \[[@b1-medscimonit-24-2655]\]. Previous studies have shown the prognostic value of insulin resistance, hyperuricemia, and dyslipidemia in the clinical outcome of PAH \[[@b5-medscimonit-24-2655]--[@b12-medscimonit-24-2655]\]. This suggests that these abnormal metabolic statuses play significant pathophysiologic roles in disease progression.

As shown in our study, prediabetes, low HDLC, and hyperuricemia were more prevalent in inoperable patients. They had a higher HbA1c and uric acid, but a lower HDLC. Results of univariate logistic regression also showed the relationship between pulmonary vascular resistance and the above-mentioned metabolic factors. However, although several reported studies have documented the relationship between hyperuricemia, low HDLC, and PAH \[[@b8-medscimonit-24-2655]--[@b12-medscimonit-24-2655]\], we only found HbA1c to be a significant risk factor for higher PVR, as shown in the multivariate logistic regression model. It is possible that hyperuricemia and low HDCL were simply 2 confounding factors associated with insulin resistance.

However, it is unclear whether insulin resistance is the cause or just a result of pulmonary arterial hypertension. Bone morphogenic protein receptor type 2 (BMPR2) is a well-known gene related to pulmonary arterial hypertension. West et al. studied the relationship between BMPR2 and pulmonary hypertension, and found that activation of BMPR2 mutation was associated with early insulin resistance \[[@b18-medscimonit-24-2655]\]. It is also possible that other undiscovered genes could predispose patients to early onset of insulin resistance and subsequent pulmonary arterial hypertension. However, insulin resistance could also be considered a result of long-term hypoxic damage of pancreatic beta cells, and Daniele et al. reported that the decreased blood flux and hypoxia caused by atherosclerosis could cause damage to beta cells \[[@b19-medscimonit-24-2655]\]. Similarly, hypoxia caused by severe PAH or the presence of right-to-left shunt could also lead to dysfunction of beta cells and subsequent prediabetic or diabetic conditions, which may subsequently aggravate PAH.

Although the hypotheses mentioned above have not yet been confirmed, it is clear that the prediabetic condition will further damage the pulmonary vascular system and contribute to disease progression. High glucose concentrations induce mitogen-activated protein kinase/phosphatidylinositol 3-kinase(PI3K)-dependent upregulation of PDGF receptor-beta and potentiate migration and proliferation of smooth muscle cells (SMC) \[[@b20-medscimonit-24-2655],[@b21-medscimonit-24-2655]\]. The inflammatory milieu associated with IR, as demonstrated by high levels of pro-inflammatory biomarkers such as C-reactive protein, interleukin-6, and myeloperoxidase, is thought to underlie the associated endothelial dysfunction and vascular disease \[[@b22-medscimonit-24-2655]\]. These are all key factors associated with vascular remodeling, which results in higher pulmonary vascular resistance.

Thus, no matter which is the cause, it is crucial to stop this vicious cycle, hoping to slow disease progression or even reverse it. For patients with persistent left-to-right shunting, insulin resistance or prediabetes could probably serve as a second insult that accelerates the onset or progression of pulmonary vascular disease and pulmonary arterial hypertension \[[@b22-medscimonit-24-2655]\]. Thus, it is possible that correcting this derangement would improve hemodynamic or pulmonary vascular disease in patients with congenital heart diseases. Several investigators have demonstrated that antidiabetic drugs like pioglitazone and metformin might reverse SMC proliferation and vascular remodeling in PAH patients \[[@b13-medscimonit-24-2655],[@b23-medscimonit-24-2655]--[@b25-medscimonit-24-2655]\]. With the concept of "treat and close" for those previously inoperable cardiac shunts, modifying the metabolic dysfunction in combination with pulmonary vasodilators is an exciting prospect for the treatment of this devastating illness and would make conditions more favorable for repair.

Limitations
-----------

Although there are several hypotheses that could explain this phenomenon, a cause-effect relationship cannot be confirmed due to the cross-sectional nature of this study. In addition, we used HbA1c as an indicator of insulin resistance, and this estimation may not be accurate. Also, the relatively small number of patients without follow-up data may be another limitation. Mechanistic studies to determine the effect of metabolic disturbances on pulmonary circulation and randomized controlled studies to detect the therapeutic effect of antidiabetic drugs on CHD-PAH are warranted.

Conclusions
===========

In conclusion, although prediabetes, hyperuricemia, and dyslipidemia were all more prevalent in patients with inoperable left-to-right shunts, only prediabetes was found to be significantly related to higher pulmonary vascular resistance. However, whether improving insulin resistance prevents or reverses vascular remodeling, thereby allowing inoperable patients to receive surgery, is in need of further investigation.
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![Comparisons of metabolic status in patients with operable *vs.* inoperable left-to-right shunts. Patients receiving defect correction had a lower HbA1c (**B**: 5.52±0.49 *vs.* 5.71±0.41, p=0.042) and uric acid (**C**: 358±105 *vs.* 406±126, p=0.029) but a higher HDLC (**D**: 1.21±0.33 *vs.* 1.08±0.22,p=0.017) and BMI (**A**: 20.4±3.9 *vs.* 18.8±3.1, p=0.023).](medscimonit-24-2655-g001){#f1-medscimonit-24-2655}

![Prevalence of insulin resistance, hyperuricemia, dyslipidemia, and obesity in operable and inoperable groups. According to the above-defined metabolic disturbances, patients in the inoperable group had a higher prevalence of prediabetes/insulin resistance (58% *vs.* 41%, p=0.076), hyperuricemia (37.2% *vs.* 21.9, p=0.106), and dyslipidemia (74% *vs.* 56%, p=0.049) but lower prevalence of hypertension (13.9% *vs.* 30.1%, p=0.049) and obesity (4.6% *vs.* 12.3%, p=0.301).](medscimonit-24-2655-g002){#f2-medscimonit-24-2655}

###### 

Comparisons of patients' demographics, laboratory blood tests and hemodynamic details.

                     Operable (n=73)   Inoperable (n=43)   p Value
  ------------------ ----------------- ------------------- ----------
  AGE (years)        42±14             33±11               \<0.0001
  BMI (kg/m^2^)      20.4±3.9          18.8±3.1            0.023
  HbA1c (%)          5.52±0.49         5.71±0.41           0.042
  NTproBNP (pg/ml)   779.2±1317        787±1398            0.974
  CREA (umol/l)      66.8±17.3         64.9±18.9           0.601
  UA (mmol/l)        358±105           406±126             0.029
  HGB (g/l)          135±14            150±33              0.001
  CHOL (mmol/l)      4.31±0.8          4.08±0.71           0.126
  TRIG (mmol/l)      1.05±0.52         1.01±0.33           0.644
  HDLC (mmol/l)      1.21±0.33         1.08±0.22           0.017
  LDLC (mmol/l)      2.52±0.71         2.44±0.64           0.054
  HR (bpm)           81±11             83±12               0.522
  RA (mmHg)          6.5±3.4           6.5±3.3             0.99
  MPAP (mmHg)        36.8±18           70.6±13.4           \<0.0001
  PAWP (mmHg)        10±3              10.5±2.8            0.372
  OXYGEN (%)         70.3±8.3          66.9±6.6            0.024
  QP/QS              2.3±0.9           0.97±0.29           \<0.0001
  CI (L/min)         3.52±0.96         3.7±0.95            0.234
  PVR (woods)        3.79±2.9          15.5±6.7            \<0.0001
  SVR (woods)        18.3±6.6          16.5±4.8            0.127
  PVR/SVR            0.21±0.13         0.96±0.38           \<0.0001

BMI -- body mass index; CREA -- creatinine; UA -- uric acid; HGB -- hemoglobin; CHOL -- cholesterol; TRIG -- triglyceride; HDLC -- high density lipoprotein cholesterol; LDLC -- low density lipoprotein cholesterol; HR -- heart rate; RA -- right atrial pressure; MPAP -- mean pulmonary arterial pressure; PAWP -- pulmonary artery wedge pressure; OXYGEN -- mixed venous oxygen saturation; QP/QS -- the ratio of pulmonary circulation and systemic circulation; CI -- cardiac index; PVR -- pulmonary vascular resistance; SVR -- systemic vascular resistance; PVR/SVR -- the ratio of pulmonary vascular resistance and systemic vascular resistance. Data are presented as means ±SD.

###### 

Univariate and multivariate logistic regression between potential risk factors and PVR.

  Variable   HR (95%CI)                P value   HR (95%CI)               P value
  ---------- ------------------------- --------- ------------------------ ----------
  Age        −0.056 (−0.089, −0.023)   0.001     −0.08 (−0.12, −0.036)    \<0.0001
  Gender     0.417 (−0.44, 1.25)       0.343     --                       --
  BMI        −0.13 (−0.24, −0.015)     0.026     −0.13 (−0.26, −0.0005)   0.051
  HbA1c      0.87 (0.02, 1.7)          0.045     1.76 (0.53, 2.99)        0.005
  UA         0.004 (0.0003, 0.0007)    0.035     0.003 (0.0013, 0.0073)   0.165
  HDLC       −1.53 (−2.93, −0.12)      0.034     −1.1 (−2.74, 0.54)       0.187
  CHOL       −0.40 (−0.91, 0.11)       0.128     --                       --
  TRIG       −0.19 (−1.04, 0.64)       0.641     --                       --
  LDLC       −0.17 (−0.72, 0.38)       0.343     --                       --
  shtn       −0.03 (−0.06, −0.005)     0.019     −0.03 (−0.07, −0.016)    0.202
  dhtn       −0.03 (−0.06, −0.008)     0.121     --                       --

PVR -- pulmonary vascular resistance; BMI -- body mass index; UA -- uric acid; CHOL -- cholesterol; TRIG -- triglyceride; HDLC -- high density lipoprotein cholesterol; LDLC -- low density lipoprotein cholesterol; shtn -- systolic blood pressure; dhtn -- diastolic blood pressure.
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